Third Rock Ventures

Third Rock Ventures has launched over 50 life science companies since 2007. Its portfolio has brought at least 16 products to market addressing significant unmet medical needs in areas such as cancer and rare disease. The firm’s approach involves hands-on company creation from discovery through launch and growth phases. Recent investments include Merida Biosciences ($121M Series A for precision immunology), Trace Neuroscience ($101M Series A for neurodegenerative disease genomics), among others. Portfolio highlights include FDA approvals for bluebird bio’s Lyfgenia gene therapy for sickle cell disease and Element Science’s Jewel® Patch Wearable Cardioverter Defibrillator.